28
Participants
Start Date
October 27, 2015
Primary Completion Date
March 10, 2021
Study Completion Date
March 10, 2021
KX01 0.01% (0.1 mg/g)
Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
Placebo
Contains same excipients with KX01 but do not contain Tirbanibulin
KX01 0.1% (1.0 mg/g)
Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
KX01 1% (10 mg/g) for 5 days
Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Lead Sponsor
PharmaEssentia
INDUSTRY